

**Date: 25 August 2021**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Nephromag, kit for radiopharmaceutical preparation**

**1. NAME OF THE MEDICINAL PRODUCT**

 Nephromag

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

The kit contains two different vials: (1) and (2).

Vial (1) contains 0.2 mg of the mertiatide (mercaptoacetyltriglycine).

Vial (2) contains 2.5 mL phosphate buffer solution.

For a full list of excipients, see section 6.1.

The radionuclide is not part of the kit. The kit contains all non-radioactive components required for the reconstitution of technetium-(99mTc) mertiatide solution for injection.

**3. PHARMACEUTICAL FORM**

Kit for radiopharmaceutical preparation.

Vial 1: white to off-white powder

Vial 2: clear, colourless solution

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

This medicinal product is for diagnostic use only. After radiolabelling with sodium pertechnetate(99mTc) solution, the solution of technetium-(99mTc) mertiatide, is used for the evaluation of nephrological and urological disorders in particular for the study of function, morphology and perfusion of the kidneys and characterisation of urinary outflow.

**4.2 Posology and method of administration**

Posology

*Adults and elderly population*

40 - 200 MBq, depending on the pathology to be studied and the method to be used.

*Paediatric population*

The use in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group. The activities to be administered to children and to adolescents may be calculated according to the recommendations of the European Association of Nuclear Medicine (EANM) paediatric dosage card; the activity administered to children and to adolescents may be calculated by multiplying a baseline activity (for calculation purposes) by the weight-dependent multiples given in the table below.

A[MBq]Administered = Baseline Activity × Multiple

The baseline activity is 11.9 MBq.

The minimum activity is 15 MBq.

|  |  |  |  |
| --- | --- | --- | --- |
| **Weight kg** | **Multiple** | **Weightkg** | **Multiple** |
| **3** | 1 | **32** | 3.77 |
| **4** | 1.12 | **34** | 3.88 |
| **6** | 1.47 | **36** | 4.00 |
| **8** | 1.71 | **38** | 4.18 |
| **10** | 1.94 | **40** | 4.29 |
| **12** | 2.18 | **42** | 4.41 |
| **14** | 2.35 | **44** | 4.53 |
| **16** | 2.53 | **46** | 4.65 |
| **18** | 2.71 | **48** | 4.77 |
| **20** | 2.88 | **50** | 4.88 |
| **22** | 3.06 | **52-54** | 5.00 |
| **24** | 3.18 | **56-58** | 5.24 |
| **26** | 3.35 | **60-62** | 5.47 |
| **28** | 3.47 | **64-66** | 5.65 |
| **30** | 3.65 | **68** | 5.77 |

Method of administration

For intravenous use.

This medicinal product should be reconstituted before administration to the patient.

The scintigraphic investigation is usually started immediately after administration.

For patient preparation, see section 4.4

For instructions on reconstitution and labelling of the medicinal product before administration, see section 12.

**4.3 Contraindications**

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to any of the components of the labelled radiopharmaceutical.

**4.4 Special warnings and precautions for use**

Potential for hypersensitivity or anaphylactic reactions

If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available.

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.

Paediatric population

Paediatric population, see sections 4.2.

Careful consideration of the indication is required since the effective dose per MBq is higher than in adults (see section 11 “Dosimetry”).

Patient preparation

The patient should be well hydrated before the start of the examination and urged to void as often as possible during the first hours after the examination in order to reduce radiation.

Specific warnings

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.

Precautions with respect to environmental hazard see section 6.6.

**4.5 Interaction with other medicinal products and other forms of interaction**

Technetium-(99mTc) mertiatide is not known to interfere with agents commonly prescribed to patients requiring the above-mentioned investigations (e.g. antihypertensives or medicinal agents used to treat or prevent organ transplant rejection).

Under the influence of tubulary secreted hydrochlorothiazide a reduced tubular secretion of the product has to be expected. This can in principle occur with other drugs that are secreted in the proximal tubule (e.g. nonsteroidal anti-inflammatory drugs).

The previous administration of substances such as benzylpenicillin or iodinated contrast media may also cause lower efficiency of the transport mechanism of the tubular cells.

It is reported that co-administration of metoclopramide reduces renal plasma flow. Therapeutic doses may result in reduced clearance values. Dehydration and acidosis can also cause a prolonged elimination of the product.

**4.6 Pregnancy and lactation**

Women of childbearing potential

When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques not using ionising radiation (if there are any) should be offered to the patient.

Pregnancy

Radionuclide procedures carried out on a pregnant woman also involve radiation doses to the foetus.

Only imperative investigations should therefore be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus.

Breastfeeding

Before administering a radioactive medicinal product to a mother who is breastfeeding consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breastfeeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity into breast milk.

If the administration of 99mTc- mertiatide is considered necessary, breast-feeding should be interrupted for 4 hours and the expressed feeds discarded, according to the recommendation of ICRP 128.

Fertility

Effects on fertility are not known.

**4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been performed.

**4.8 Undesirable effects**

|  |  |
| --- | --- |
| **Nervous system disorder**Not known (cannot be estimated from the available data) | Cerebral convulsion1. |
| **Immune system disorders**Very rare (<1/10,000) | Mild anaphylactoid reactions such as urticarial rash, swelling of eyelids and coughing. |

1 Seen in a 15 days old child. Causal relationship not established.

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. For diagnostic nuclear medicine investigations the current evidence suggests that these adverse effects will occur with low frequency because of the low radiation doses incurred.

For most diagnostic nuclear medical procedures, the radiation dose delivered (E) is less than 20 mSv. A worst case calculation for the procedure in question gives values of 2 mSv for an adult and 0.76 mSv for a 1 year old child after injection of 200 and 20 MBq respectively.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Websted: [www.meldenbivirkning.dk](http://www.meldenbivirkning.dk)

**4.9 Overdose**

In the event of administration of a radiation overdose with technetium-(99mTc) mertiatide the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition or and frequent bladder voiding. It might be helpful to estimate the effective dose that was applied.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Diagnostic radiopharmaceuticals, renal system, technetium (99mTc) compounds.

ATC Code: V09CA03

No pharmaco-dynamic effect is known for technetium-(99mTc) mertiatide at the chemical doses envisaged.

Measuring the counts rate in the kidneys, over time, allows the evaluation of the renal perfusion, function and urinary outflow.

**5.2 Pharmacokinetic properties**

Distribution

After intravenous injection technetium-(99mTc) mertiatide is rapidly cleared from the blood by the kidneys.

Organ uptake

Technetium-(99mTc) mertiatide binds in a 78-90 % proportion to plasma proteins. In normal renal function 70 % of the administered activity is excreted within 30 min. and more than 95 % within 3 hours. These values are dependent on the pathology of the kidneys and the urogenital system.

Elimination

The mechanism of excretion is predominantly based on tubular secretion. Glomerular filtration accounts for 11 % of total clearance.

**5.3 Preclinical safety data**

It has been reported that no acute, subacute, subchronic or mutagenic effects have been observed in preclinical studies. However, no detailed information is available for these studies.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Vial (1):

Stannous chloride dihydrate,

Disodium (R,R)-tartrate dihydrate

Sodium hydroxide

Hydrochloric acid

**Vial (2):**

Sodium monohydrogenphosphate dihydrate

Sodium dihydrogenphosphate dihydrate

Hydrochloric acid

Water for injections

**6.2 Incompatibilities**

Not known. However, in order not to compromise the stability of technetium-(99mTc) mertiatide, preparations should not be administered together with other drugs.

**6.3 Shelf life**

15 months

After radiolabelling: 8 hours.

Store the radiolabelled preparation at 25 °C.

**6.4 Special precautions for storage**

Store in a refrigerator (2 – 8 °C).

Store in the original package in order to protect from light.

For storage conditions of the radiolabelled medicinal product, see section 6.3

Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive material.

**6.5 Nature and contents of container**

Glass vial (10 mL) closed with a butyl rubber stopper and sealed with an aluminium crimpcap. Nephromag 0.2 mg kit for radiopharmaceutical preparation is supplied in packages containing five vials with powder (active substance: mertiatide) and five vials with 2.5 mL sterile phosphate buffer solution.

**6.6 Special precautions for disposal and other handling**

General warning

Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

Contents of the vial are intended only for use in the preparation of technetium (99mTc) mertiatide and are not to be administered directly to the patient without first undergoing the preparative procedure.

Precautions to be taken before handling or administration of the medicinal product

For instructions on reconstitution and labelling of the medicinal product before administration, see section 12.

If at any time in the preparation of this product the integrity of this vial is compromised it should not be used.

Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The content of the kit before reconstitution is not radioactive. However, after sodium pertechnetate (99mTc) Injection, Ph. Eur. is added, adequate shielding of the final preparation must be maintained.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting etc. Radiation protection precautions in accordance with national regulations must therefore be taken.

Any unused product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

ROTOP Pharmaka GmbH

Bautzner Landstraße 400

01328 Dresden

Germany

**8. MARKETING AUTHORISATION NUMBER(S)**

56213

**9. DATE OF FIRST AUTHORISATION**

15 December 2016

**10. DATE OF REVISION OF THE TEXT**

25 August 2021

**11. DOSIMETRY**

Technetium (99mTc) is produced by means of a (99Mo/99mTc) generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable.

The data listed below are from ICRP publication 80 in 1998 and are calculated according to the MIRD system:

The following assumptions have been made in this model:

* In the normal case following intravenous administration of MAG3, the substance is rapidly distributed in the extracellular fluid and excreted entirely by the renal system according to the kidney-bladder model. Total body retention is described by a three-exponential function. The renal transit time is assumed to be 4 minutes as for Hippuran.
* When renal function is bilaterally impaired, it is assumed that the clearance rate of the substance is one tenth of that of the normal case, that the renal transit time is increased to 20 minutes, and that a fraction of 0.04 is taken up in the liver.
* As an example of acute unilateral renal blockage, it is assumed that a fraction of 0.5 of the administered radiopharmaceutical is taken up by one kidney and slowly released to the blood with a half-time of 5 days and subsequently excreted by the other kidney, which is assumed to function normally.

Normal renal function

|  |
| --- |
| **Absorbed doses: Technetium (99mTc) mertiatide** |
|   | Dose absorbed per activity administered [mGy/MBq] |
| Organ | Adults | 15 year old | 10 year old | 5 year old  | 1 year old |
|   |  |  |  |  |   |
| Adrenals | 0.00039 | 0.00051 | 0.00082 | 0.00120 | 0.00250 |
| Bladder | 0.11000 | 0.14000 | 0.17000 | 0.18000 | 0.32000 |
| Bone surfaces | 0.00130 | 0.00160 | 0.00210 | 0.00240 | 0.00430 |
| Brain | 0.00010 | 0.00013 | 0.00022 | 0.00035 | 0.00061 |
| Breast | 0.00010 | 0.00014 | 0.00024 | 0.00039 | 0.00082 |
| Gall bladder | 0.00057 | 0.00087 | 0.00200 | 0.00170 | 0.00280 |
| GI-tract |  |  |  |  |   |
|  Stomach | 0.00039 | 0.00049 | 0.00097 | 0.00130 | 0.00250 |
|  SI | 0.00230 | 0.00300 | 0.00420 | 0.00460 | 0.00780 |
|  Colon | 0.00340 | 0.00430 | 0.00590 | 0.00600 | 0.00980 |
|  ULI | 0.00170 | 0.00230 | 0.00340 | 0.00400 | 0.00670 |
|  LLI | 0.00570 | 0.00700 | 0.00920 | 0.00870 | 0.01400 |
|   |  |  |  |  |   |
| Heart | 0.00018 | 0.00024 | 0.00037 | 0.00057 | 0.00120 |
| Kidneys | 0.00340 | 0.00420 | 0.00590 | 0.00840 | 0.01500 |
| Liver | 0.00031 | 0.00043 | 0.00075 | 0.00110 | 0.00210 |
| Lungs | 0.00015 | 0.00021 | 0.00033 | 0.00050 | 0.00100 |
| Muscles | 0.00140 | 0.00170 | 0.00220 | 0.00240 | 0.00410 |
|   |  |  |  |  |   |
| Oesophagus | 0.00013 | 0.00018 | 0.00028 | 0.00044 | 0.00082 |
| Ovaries | 0.00540 | 0.00690 | 0.00870 | 0.00870 | 0.01400 |
| Pancreas | 0.00040 | 0.00050 | 0.00093 | 0.00130 | 0.00250 |
| Red marrow | 0.00093 | 0.00120 | 0.00160 | 0.00150 | 0.00210 |
| Skin | 0.00046 | 0.00057 | 0.00083 | 0.00097 | 0.00180 |
|   |  |  |  |  |   |
| Spleen | 0.00036 | 0.00049 | 0.00079 | 0.00120 | 0.00230 |
| Testes | 0.00370 | 0.00530 | 0.00810 | 0.00870 | 0.01600 |
| Thymus | 0.00013 | 0.00018 | 0.00028 | 0.00044 | 0.00082 |
| Thyroid | 0.00013 | 0.00016 | 0.00027 | 0.00044 | 0.00082 |
| Uterus | 0.01200 | 0.01400 | 0.01900 | 0.01900 | 0.03100 |
| Remaining organs | 0.00130 | 0.00160 | 0.00210 | 0.00220 | 0.00360 |
| **Effective dose (mSv/MBq)** | **0.00700** | **0.00900** | **0.01200** | **0.01200** | **0.02200** |
| Bladder wall contributes up to 80% of the effective dose. |
| *Effective dose if the bladder is emptied 1 or 0.5 hours after administration:* |
| 1 hour | 0.00250 | 0.00310 | 0.00450 | 0.00640 | 0.00640 |
| 30 min | 0.00170 | 0.00210 | 0.00290 | 0.00390 | 0.00680 |

Abnormal renal function

|  |
| --- |
| **Absorbed doses: Technetium (99mTc) mertiatide**  |
|   | Dose absorbed per activity administered [mGy/MBq] |
| Organ | Adults | 15 year old | 10 year old | 5 year old | 1 year old |
|   |  |  |  |  |   |
| Adrenals | 0.00160 | 0.00210 | 0.00320 | 0.00480 | 0.00860 |
| Bladder | 0.08300 | 0.11000 | 0.13000 | 0.13000 | 0.23000 |
| Bone surfaces | 0.00220 | 0.00270 | 0.00380 | 0.00500 | 0.00910 |
| Brain | 0.00061 | 0.00077 | 0.00130 | 0.00200 | 0.00360 |
| Breast | 0.00054 | 0.00070 | 0.00110 | 0.00170 | 0.00320 |
| Gall bladder | 0.00160 | 0.00220 | 0.00380 | 0.00460 | 0.00640 |
| GI-tract |  |  |  |  |   |
|  Stomach | 0.00120 | 0.00150 | 0.00260 | 0.00350 | 0.00610 |
|  SI | 0.00270 | 0.00350 | 0.00500 | 0.00600 | 0.01000 |
|  Colon | 0.00350 | 0.00440 | 0.00610 | 0.00690 | 0.01100 |
|  ULI | 0.00220 | 0.00300 | 0.00430 | 0.00560 | 0.00930 |
|  LLI | 0.00510 | 0.00630 | 0.00850 | 0.00860 | 0.01400 |
|   |  |  |  |  |   |
| Heart | 0.00091 | 0.00120 | 0.00180 | 0.00270 | 0.00480 |
| Kidneys | 0.01400 | 0.01700 | 0.02400 | 0.03400 | 0.05900 |
| Liver | 0.00140 | 0.00180 | 0.00270 | 0.00380 | 0.00660 |
| Lungs | 0.00079 | 0.00110 | 0.00160 | 0.00240 | 0.00450 |
| Muscles | 0.00170 | 0.00210 | 0.00290 | 0.00360 | 0.00640 |
|   |  |  |  |  |   |
| Oesophagus | 0.00074 | 0.00097 | 0.00150 | 0.00230 | 0.00410 |
| Ovaries | 0.00490 | 0.00630 | 0.00810 | 0.00870 | 0.01400 |
| Pancreas | 0.00150 | 0.00190 | 0.00290 | 0.00430 | 0.00740 |
| Red marrow | 0.00150 | 0.00190 | 0.26000 | 0.00310 | 0.00500 |
| Skin | 0.00078 | 0.00096 | 0.00150 | 0.00200 | 0.00380 |
|   |  |  |  |  |   |
| Spleen | 0.00150 | 0.00190 | 0.00290 | 0.00430 | 0.00740 |
| Testes | 0.00340 | 0.00470 | 0.00710 | 0.00780 | 0.01400 |
| Thymus | 0.00074 | 0.00097 | 0.00150 | 0.00230 | 0.00410 |
| Thyroid | 0.00073 | 0.00095 | 0.00150 | 0.00240 | 0.00440 |
| Uterus | 0.01000 | 0.01200 | 0.01600 | 0.01600 | 0.02700 |
| Remaining organs | 0.00170 | 0.00210 | 0.00280 | 0.00340 | 0.00600 |
| **Effective dose (mSv/MBq)** | **0.00610** | **0.00780** | **0.01000** | **0.01100** | **0.19000** |

Acute unilateral renal blockage

|  |
| --- |
| **Absorbed doses: Technetium (99mTc) mertiatide**  |
|   | Dose absorbed per activity administered [mGy/MBq] |
| Organ | Adults | 15 year old | 10 year old | 5 year old | 1 year old |
|   |  |  |  |  |   |
| Adrenals | 0.01100 | 0.01400 | 0.02200 | 0.03200 | 0.05500 |
| Bladder | 0.05600 | 0.07100 | 0.09100 | 0.09300 | 0.17000 |
| Bone surfaces | 0.00310 | 0.00400 | 0.00580 | 0.00840 | 0.01700 |
| Brain | 0.00011 | 0.00014 | 0.00023 | 0.00039 | 0.00075 |
| Breast | 0.00038 | 0.00051 | 0.00100 | 0.00160 | 0.00300 |
| Gall bladder | 0.00620 | 0.00730 | 0.01000 | 0.01600 | 0.02300 |
| GI-tract |  |  |  |  |   |
|  Stomach | 0.00390 | 0.00440 | 0.00700 | 0.00930 | 0.01200 |
|  SI | 0.00430 | 0.00550 | 0.00850 | 0.01200 | 0.01900 |
|  Colon | 0.00390 | 0.00500 | 0.00720 | 0.00920 | 0.00150 |
|  ULI | 0.00400 | 0.00510 | 0.00760 | 0.01000 | 0.01600 |
|  LLI | 0.00380 | 0.00480 | 0.00670 | 0.00820 | 0.01300 |
|   |  |  |  |  |   |
| Heart | 0.00130 | 0.00160 | 0.00270 | 0.00400 | 0.00610 |
| Kidneys | 0.20000 | 0.24000 | 0.33000 | 0.47000 | 0.81000 |
| Liver | 0.00440 | 0.00540 | 0.00810 | 0.01100 | 0.01700 |
| Lungs | 0.00110 | 0.00160 | 0.00250 | 0.00390 | 0.00720 |
| Muscles | 0.00220 | 0.00270 | 0.00370 | 0.00510 | 0.00890 |
|   |  |  |  |  |   |
| Oesophagus | 0.00038 | 0.00054 | 0.00085 | 0.00150 | 0.00230 |
| Ovaries | 0.00380 | 0.00510 | 0.00710 | 0.00920 | 0.01500 |
| Pancreas | 0.00740 | 0.00900 | 0.01300 | 0.01800 | 0.02900 |
| Red marrow | 0.00300 | 0.00360 | 0.00500 | 0.00600 | 0.00830 |
| Skin | 0.00082 | 0.00100 | 0.00150 | 0.00220 | 0.00420 |
|   |  |  |  |  |   |
| Spleen | 0.00980 | 0.01200 | 0.01800 | 0.02600 | 0.04000 |
| Testes | 0.00200 | 0.00290 | 0.00450 | 0.00500 | 0.00980 |
| Thymus | 0.00038 | 0.00054 | 0.00085 | 0.00150 | 0.00230 |
| Thyroid | 0.00017 | 0.00023 | 0.00045 | 0.00092 | 0.00160 |
| Uterus | 0.00720 | 0.00870 | 0.01200 | 0.01300 | 0.02200 |
| Remaining organs | 0.00210 | 0.00260 | 0.00360 | 0.00470 | 0.00800 |
| **Effective dose (mSv/MBq)** | **0.01000** | **0.01200** | **0.01700** | **0.02200** | **0.03800** |

The effective dose resulting from the administration of a maximal recommended activity of 200 MBq for an adult weighing 70 kg is about 1.4 mSv.

For an administered activity of 200 MBq the typical radiation dose to the target organ (kidney)is 0.68 mGy and the typical radiation dose to the critical organ bladder wallis 21.6 mGy.

**12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS**

Radiolabelling should be done using an eluate with a radioactive concentration between 40 and 500 MBq/mL. Only eluates obtained from a generator, which has been eluted once in the preceding 24 hours, should be used.

The content of vial (1) is labelled with sodium pertechnetate (99mTc) solution at room temperature. The radiolabelling reaction is stopped after 15 minutes by adding the buffer solution.

Withdrawals should be performed under aseptic conditions. The vials must not be opened before disinfecting the stopper, the solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorized automated application system.

As with any pharmaceutical product, if at any time in the preparation of this product the integrity of this vial is compromised it should not be used.

Method of preparation

The radiopharmaceutical is prepared according to the following labelling instructions immediately before use:

The radiolabelling procedure has to be carried out under aseptic conditions.

Place vial (1) into an adequate lead shielding. Swab the rubber septum with an appropriate disinfectant and let it dry.

Inject 8 mL of sodium pertechnetate (99mTc) solution into vial (1) using a syringe. Then withdraw the same volume of nitrogen from the vial with the same syringe for pressure compensation.

Shake the vial carefully in order to moisten. The complete content of the vial is for complete dissolution of any powder.

After 15 minutes reaction time transfer a volume of 2 mL buffer solution from vial (2) into vial (1) using a new syringe. Then withdraw the same volume of nitrogen from the vial with the same syringe for pressure compensation.

Shake carefully for good mixing. Determine the total radioactivity and calculate the volume to be injected.

Properties of the product after radiolabelling:

Appearance: Clear to slightly opalescent, colourless, aqueous solution.

pH: 7.1-7.5

Quality control

The following methods may be used:

**HPLC method**

The radiochemical purity of the labelled substance is examined by high performance liquid chromatography (HPLC) using a suitable detector of radioactivity, on a 25 cm RP18 column, flow rate 1.0 mL/min. Mobile phase A is a 93:7 mixture of phosphate solution (1.36 g KH2PO4, adjusted with 0.1 M NaOH to pH 6) and ethanol. Mobile phase B is a 1:9 mixture of water and methanol.

Use a gradient elution program with the following parameters:

|  |  |  |  |
| --- | --- | --- | --- |
| Time (min): | Flow (mL/min): | % A | % B |
| 10 | 1 | 100 | 0 |
| 15 | 1 | 0 | 100 |

The technetium-(99mTc) mertiatide peak appears at the end of the passage of mobile phase A.

The injection volume is 10 μl and the total count rate per channel must not exceed 30.000.

Specification:

|  |  |  |
| --- | --- | --- |
|  | t = 0 | after 8 hours |
| technetium-(99mTc) mertiatide | ≥ 94 % | ≥ 94 % |
| hydrophilic impurities (sum of the areas preceding the principal peak) | ≤ 3.0 % | ≤ 3.0 % |
| lipophilic impurities (sum of the peaks following the principal peak) | ≤ 4.0 % | ≤ 4.0 % |

**Simplified rapid procedure Sep-Pak**

This method is based on cartridges, which are widely used as sample pre-treatment of aqueous solutions for chromatography. The cartridge (e.g. Sep-Pak Plus C 18, Waters) is washed with 10 mL absolute ethanol, followed by 10 mL 0.001 M hydrochloric acid. Remaining residues of the solutions are removed by 5 mL of air.

0.05 mL technetium-(99mTc) mertiatide solution is applied on the cartridge. Elute with 10 mL of 0.001 M hydrochloric acid and collect this first eluate (hydrophilic impurities). Elute the cartridge with ethanol/ 9 g/L sodium chloride solution in a ratio of 1:1. This second eluate contains technetium-(99mTc) mertiatide. The cartridge contains the lipophilic impurities.

Measure the radioactivity of each portion. Sum up the radioactivity of the eluates and the cartridge as 100 % and calculate the respective percentages.

Be aware to elute slowly (drop wise).

Calculation:
$$Radiochemical purity \left[\%\right]=\frac{radioactivity of second eluate \left[MBq\right]}{sum of radioactivity \left[MBq\right]} ×100 \%$$

Specification: technetium-(99mTc) mertiatide ≥ 94 %

 Sum of impurities: ≤ 6.5 %

**Simplified rapid procedure ITLC-SA**

**This method is based on thin layer chromatography to determine the radiochemical purity a) [99mTc]Tc, colloidal and of b) ([99mTc]pertechnetate).**



1. **Assay of [99mTc]Tc, colloidal (impurity A)**

Chromatographic system:

TLC plate: Silica acid impregnated glass fibre strips (ITLC-SA)

Start: 1.0 cm from lower end

Solvent: water (WfI)

Sample: 1-2 µl

Running distance: 6-8 cm

Detector: a suitable detector

**Evaluation**

Detection by radio activity counters without special resolution

After development remove the strips from the chromatographic chamber, dry in air and cut it at the marked position (1.5 cm). Measure radioactivity of both parts separately. Relate activity of the part with the starting point to total activity.

Detection by Radio-Scanner:

After development remove the strip from the chromatographic chamber, dry in air fix the strip on the support of the scanner.

Measure the activity distribution and display them in a chromatogram. Calculate the percentages of the single peaks by peak integration.

$$[99mTc]Tc, colloidal in \%=\frac{Activity lower part}{Activity both parts }×100 \%$$

Specification for [99mTc]Tc, colloidal (impurity A) ≤ 2.0 %



1. **Assay of [99mTc]pertechnetate (impurity B)**

Chromatographic system:

TLC plate: Silica acid impregnated glass fibre strips (ITLC-SA)

Start: 1.0 cm from lower end

Solvent: Methyl ethyl ketone

Sample: 1-2 µl

Running distance: 6-8 cm

Detector: a suitable detector

**Evaluation**

Detection by radio activity counters without special resolution

After development remove the strip from the chromatographic chamber, dry in air and cut it at the prescribed position (5cm). Measure radioactivity of both parts separately. Relate activity of upper part to total activity.

Detection by Radio-Scanner:

After development remove the strip from the chromatographic chamber, dry in air fix the strip on the support of the scanner.

Measure the spreading of activity and display them in a chromatogram. Calculate the percentages of the single peaks.

$$[99mTc]pertechnetate in \%=\frac{Activity upper part}{Activity both parts }×100 \%$$

Specification for [99mTc]pertechnetat (impurity B) ≤ 5.0 %

**Calculation of radiochemical purity (Specification ≥ 94 %):**

Radiochemical purity = 100 % - (A [%] + B [%])